Compare VRAX & EZRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRAX | EZRA |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.1M |
| IPO Year | 2021 | 2020 |
| Metric | VRAX | EZRA |
|---|---|---|
| Price | $2.76 | $2.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | 65.5K | ★ 3.9M |
| Earning Date | 06-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 85.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,430,959.00 |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.11 |
| 52 Week High | $13.19 | $5.45 |
| Indicator | VRAX | EZRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 47.45 |
| Support Level | $2.55 | $2.03 |
| Resistance Level | $3.10 | $4.02 |
| Average True Range (ATR) | 0.18 | 0.41 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 42.61 | 20.00 |
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Reliance Global Group Inc operates as a holding company that acquires, owns, and actively manages insurance and technology-focused businesses. The company focuses on growing by pursuing acquisition strategies initially, and focuses on wholesale and retail insurance agencies. Its primary move is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations. The Company operates as a single operating segment, the Insurance Segment, earning its revenues from insurance commissions.